I
Icosavax
Biotech & Life Sciences · Seattle, United States · Founded 2018 · IPO 2021
Developing safe and effective vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses MoreLess
Icosavax, founded in 2017, is a clinical-stage biotechnology company focused on developing vaccines to protect vulnerable older adults from severe respiratory infections. The company leverages a novel approach using virus-like particles (VLPs) that mimic the structure of viruses to elicit a stronger immune response. Icosavax operates in the biotechnology and healthcare market, primarily serving older adults who are at higher risk for respiratory diseases. The company's business model involves the discovery, development, and commercialization of VLP-based vaccines. Revenue is generated through partnerships, licensing agreements, and eventual vaccine sales. As a member of the AstraZeneca Group, Icosavax benefits from extensive resources and expertise in the pharmaceutical industry.
Keywords: VLP-based vaccines, respiratory infections, older adults, biotechnology, healthcare, immune response, clinical-stage, AstraZeneca, vaccine development, infectious diseases.
Company overview
Icosavax company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Seattle, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 62.5
Valuation & funding
Icosavax funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $1.1B | $1.1B | AstraZeneca | ↗ |
| POST IPO EQUITYOther financing | May 2023 | $68M | — | Vivo Capital · TCGX · Logos Capital | ↗ |
| IPOOther financing | Jul 2021 | $0 | — | Undisclosed | — |
| SERIES BOther financing | Apr 2021 | $100M | $400M | Adams Street Partners · Citadel · Cormorant Asset Management · Qiming Venture Partners USA | — |
| GRANTOther financing | Oct 2020 | $17M | — | Bill & Melinda Gates Foundation · Open Philanthropy Project | — |
| SERIES AOther financing | Oct 2019 | Qiming Venture Partners USA | — | ||
| SPINOUTOther financing | Jan 2018 | University of Washington · University of Washington Institute for Protein Design | — | ||
| SEEDOther financing | Jan 2018 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1M | 0% | −$95M | -9505.8% |
| 2025 | $1M | -33.3% | −$95M | -9505.8% |
| 2024 | $1.5M | +200% | −$95M | -6337.2% |
| 2023 | $500K | — | −$95M | -19011.6% |
| 2022 | $0 | — | −$95M | — |
| 2021 | $0 | — | −$65M | — |
| 2020 | $0 | — | −$19M | — |
Growth signals
Icosavax website traffic
Latest recorded traffic for Icosavax is 770 monthly website visits, down 45% over the last three months. Icosavax's team grew 0% over the past year.
Comparisons
Icosavax compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Icosavax's talent
Source: Dealroom Talent Intelligence.
Investors
19 investors on Icosavax's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Icosavax has talent and traffic
In the news
Latest news about Icosavax
Recent press, funding announcements, and product moves mentioning Icosavax — open to read from the original sources.
Market sentiment
What the market is saying about Icosavax
An AI-synthesized read of the highest-engagement posts about Icosavax on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Icosavax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.